Skip to main content
Top
Published in: Endocrine 3/2011

01-12-2011 | Original Article

Association between the T869C polymorphism of transforming growth factor-beta 1 and diabetic nephropathy: a meta-analysis

Authors: Hongxia Jia, Lili Yu, Bin Gao, Qiuhe Ji

Published in: Endocrine | Issue 3/2011

Login to get access

Abstract

Accumulating evidence has suggested that transforming growth factor-beta 1 (TGF-β1) is a functional candidate for diabetic nephropathy (DN). However, association studies investigating the relationship of TGF-β1 gene T869C polymorphism and DN generate inconsistent results. To comprehensively clarify this issue, we performed a meta-analysis to evaluate the impact of the polymorphism on DN. We searched studies from PubMed and China National Knowledge Infrastructure (CNKI) through March 2011. Pooled ORs were calculated under allelic/additive/dominant/recessive/over-dominant genetic models. Nine studies with 1776 cases and 1740 controls were included. Our results indicated that C allele of T869C conferred a significantly increased risk of DN compared with T allele (OR = 1.25, 95% CI: 1.05–1.48) for allelic contrast. Similar results were also found under additive (OR = 1.57, 95% CI: 1.10–2.23) and dominant (OR = 1.40, 95% CI: 1.06–1.85) genetic models. However, subgroup analyses stratified by types of diabetes showed that significantly increased risks were only observed in type 2 diabetic patients, and the association persistently existed in further analysis for Asian populations. As for type 1 diabetic subjects, no significant association was detected under all the genetic models (P > 0.05). Our meta-analysis suggested that the TGF-β1 T869C polymorphism conferred an elevated risk of DN. However, significant associations were only observed in type 2 diabetic patients.
Literature
1.
go back to reference A. Jawa, J. Kcomt, V.A. Fonseca, Diabetic nephropathy and retinopathy. Med. Clin. North. Am. 88, 1001–1036 (2004)PubMedCrossRef A. Jawa, J. Kcomt, V.A. Fonseca, Diabetic nephropathy and retinopathy. Med. Clin. North. Am. 88, 1001–1036 (2004)PubMedCrossRef
2.
go back to reference G. Remuzzi, A. Schieppati, P. Ruggenenti, Clinical practice. Nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 346, 1145–1151 (2002)PubMedCrossRef G. Remuzzi, A. Schieppati, P. Ruggenenti, Clinical practice. Nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 346, 1145–1151 (2002)PubMedCrossRef
3.
go back to reference S. Yamagishi, K. Fukami, S. Ueda, S. Okuda, Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr. Drug Targets 8, 952–959 (2007)PubMedCrossRef S. Yamagishi, K. Fukami, S. Ueda, S. Okuda, Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr. Drug Targets 8, 952–959 (2007)PubMedCrossRef
4.
go back to reference F.N. Ziyadeh, Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy. Diabetes Res. Clin. Pract. 82, S38–S41 (2008)PubMedCrossRef F.N. Ziyadeh, Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy. Diabetes Res. Clin. Pract. 82, S38–S41 (2008)PubMedCrossRef
5.
go back to reference T. Yamamoto, T. Nakamura, N.A. Noble, E. Ruoslahti, W.A. Border, Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc. Natl. Acad. Sci. USA 90, 1814–1818 (1993)CrossRef T. Yamamoto, T. Nakamura, N.A. Noble, E. Ruoslahti, W.A. Border, Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc. Natl. Acad. Sci. USA 90, 1814–1818 (1993)CrossRef
6.
go back to reference J.B. Kopp, V.M. Factor, M. Mozes, P. Nagy, N. Sanderson, E.P. Bottinger, P.E. Klotman, S.S. Thorgeirsson, Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab. Investig. 74, 991–1003 (1996)PubMed J.B. Kopp, V.M. Factor, M. Mozes, P. Nagy, N. Sanderson, E.P. Bottinger, P.E. Klotman, S.S. Thorgeirsson, Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab. Investig. 74, 991–1003 (1996)PubMed
7.
go back to reference F.N. Ziyadeh, B.B. Hoffman, D.C. Han, M.C. Iglesias-De La Cruz, S.W. Hong, M. Isono, S. Chen, T.A. McGowan, K. Sharma, Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. USA 97, 8015–8020 (2000)PubMedCrossRef F.N. Ziyadeh, B.B. Hoffman, D.C. Han, M.C. Iglesias-De La Cruz, S.W. Hong, M. Isono, S. Chen, T.A. McGowan, K. Sharma, Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. USA 97, 8015–8020 (2000)PubMedCrossRef
8.
go back to reference K. Sharma, Y. Jin, J. Guo, F.N. Ziyadeh, Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45, 522–530 (1996)PubMedCrossRef K. Sharma, Y. Jin, J. Guo, F.N. Ziyadeh, Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45, 522–530 (1996)PubMedCrossRef
9.
go back to reference D. Fujii, J.E. Brissenden, R. Derynck, U. Francke, Transforming growth factor beta gene maps to human chromosome 19 long arm and to mouse chromosome 7. Somat. Cell Mol. Genet. 12, 281–288 (1986)PubMedCrossRef D. Fujii, J.E. Brissenden, R. Derynck, U. Francke, Transforming growth factor beta gene maps to human chromosome 19 long arm and to mouse chromosome 7. Somat. Cell Mol. Genet. 12, 281–288 (1986)PubMedCrossRef
10.
go back to reference Y. Yamada, A. Miyauchi, J. Goto, Y. Takagi, H. Okuizumi, M. Kanematsu, M. Hase, H. Takai, A. Harada, K. Ikeda, Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J. Bone Miner. Res. 13, 1569–1576 (1998)PubMedCrossRef Y. Yamada, A. Miyauchi, J. Goto, Y. Takagi, H. Okuizumi, M. Kanematsu, M. Hase, H. Takai, A. Harada, K. Ikeda, Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J. Bone Miner. Res. 13, 1569–1576 (1998)PubMedCrossRef
11.
go back to reference M.M. Jahromi, B.A. Millward, A.G. Demaine, Significant correlation between association of polymorphism in codon 10 of transforming growth factor-beta1 T (29) C with type 1 diabetes and patients with nephropathy disorder. J. Interf. Cytokine Res. 30, 59–66 (2010)CrossRef M.M. Jahromi, B.A. Millward, A.G. Demaine, Significant correlation between association of polymorphism in codon 10 of transforming growth factor-beta1 T (29) C with type 1 diabetes and patients with nephropathy disorder. J. Interf. Cytokine Res. 30, 59–66 (2010)CrossRef
12.
go back to reference E. Zintzaras, J.P. Ioannidis, Heterogeneity testing in meta-analysis of genome searches. Genet. Epidemiol. 28, 123–137 (2005)PubMedCrossRef E. Zintzaras, J.P. Ioannidis, Heterogeneity testing in meta-analysis of genome searches. Genet. Epidemiol. 28, 123–137 (2005)PubMedCrossRef
13.
go back to reference J.P. Higgins, S.G. Thompson, Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539–1558 (2002)PubMedCrossRef J.P. Higgins, S.G. Thompson, Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539–1558 (2002)PubMedCrossRef
14.
15.
go back to reference F. Pociot, P.M. Hansen, A.E. Karlsen, B.L. Langdahl, J. Johannesen, J. Nerup, TGF-beta1 gene mutations in insulin-dependent diabetes mellitus and diabetic nephropathy. J. Am. Soc. Nephrol. 9, 2302–2307 (1998)PubMed F. Pociot, P.M. Hansen, A.E. Karlsen, B.L. Langdahl, J. Johannesen, J. Nerup, TGF-beta1 gene mutations in insulin-dependent diabetes mellitus and diabetic nephropathy. J. Am. Soc. Nephrol. 9, 2302–2307 (1998)PubMed
16.
go back to reference S. Nair, A.O. Phillips, N. Norton, G. Spurlock, H.J. Williams, K.J. Craig, J.D. Williams, N.M. Williams, T. Bowen, Further evidence for the association of MMP9 with nephropathy in type 2 diabetes and application of DNA pooling technology to candidate gene screening. J. Nephrol. 21, 400–405 (2008)PubMed S. Nair, A.O. Phillips, N. Norton, G. Spurlock, H.J. Williams, K.J. Craig, J.D. Williams, N.M. Williams, T. Bowen, Further evidence for the association of MMP9 with nephropathy in type 2 diabetes and application of DNA pooling technology to candidate gene screening. J. Nephrol. 21, 400–405 (2008)PubMed
17.
go back to reference P. Prasad, A.K. Tiwari, K.M. Kumar, A.C. Ammini, A. Gupta, R. Gupta, B.K. Thelma, Association of TGFbeta1, TNFalpha, CCR2 and CCR5 gene polymorphisms in type-2 diabetes and renal insufficiency among Asian Indians. BMC Med. Genet. 8, 20–25 (2007)PubMedCrossRef P. Prasad, A.K. Tiwari, K.M. Kumar, A.C. Ammini, A. Gupta, R. Gupta, B.K. Thelma, Association of TGFbeta1, TNFalpha, CCR2 and CCR5 gene polymorphisms in type-2 diabetes and renal insufficiency among Asian Indians. BMC Med. Genet. 8, 20–25 (2007)PubMedCrossRef
18.
go back to reference Y. Akai, H. Sato, H. Ozaki, M. Iwano, Y. Dohi, M. Kanauchi, Association of transforming growth factor-beta1 T29C polymorphism with the progression of diabetic nephropathy. Am. J. Kidney Dis. 38, S182–S185 (2001)PubMedCrossRef Y. Akai, H. Sato, H. Ozaki, M. Iwano, Y. Dohi, M. Kanauchi, Association of transforming growth factor-beta1 T29C polymorphism with the progression of diabetic nephropathy. Am. J. Kidney Dis. 38, S182–S185 (2001)PubMedCrossRef
19.
go back to reference A. Patel, W.R. Scott, P.A. Lympany, J.D. Rippin, G.V. Gill, A.H. Barnett, S.C. Bain, The TGF-beta 1 gene codon 10 polymorphism contributes to the genetic predisposition to nephropathy in Type 1 diabetes. Diabet. Med. 22, 69–73 (2005)PubMedCrossRef A. Patel, W.R. Scott, P.A. Lympany, J.D. Rippin, G.V. Gill, A.H. Barnett, S.C. Bain, The TGF-beta 1 gene codon 10 polymorphism contributes to the genetic predisposition to nephropathy in Type 1 diabetes. Diabet. Med. 22, 69–73 (2005)PubMedCrossRef
20.
go back to reference T.Y. Wong, P. Poon, K.M. Chow, C.C. Szeto, M.K. Cheung, P.K. Li, Association of transforming growth factor-beta (TGF-beta) T869C (Leu 10Pro) gene polymorphisms with type 2 diabetic nephropathy in Chinese. Kidney Int. 63, 1831–1835 (2003)PubMedCrossRef T.Y. Wong, P. Poon, K.M. Chow, C.C. Szeto, M.K. Cheung, P.K. Li, Association of transforming growth factor-beta (TGF-beta) T869C (Leu 10Pro) gene polymorphisms with type 2 diabetic nephropathy in Chinese. Kidney Int. 63, 1831–1835 (2003)PubMedCrossRef
21.
go back to reference T.S. Ahluwalia, M. Khullar, M. Ahuja, H.S. Kohli, A. Bhansali, V. Mohan, R., Venkatesan, T.S. Rai, K. Sud, P.K. Singal, Common variants of inflammatory cytokine genes are associated with risk of nephropathy in type 2 diabetes among Asian Indians. PLoS One 4, e5168 (2009). T.S. Ahluwalia, M. Khullar, M. Ahuja, H.S. Kohli, A. Bhansali, V. Mohan, R., Venkatesan, T.S. Rai, K. Sud, P.K. Singal, Common variants of inflammatory cytokine genes are associated with risk of nephropathy in type 2 diabetes among Asian Indians. PLoS One 4, e5168 (2009).
22.
go back to reference A.J. McKnight, D.A. Savage, C.C. Patterson, D. Sadlier, A.P. Maxwell, Resequencing of genes for transforming growth factor beta1 (TGFB1) type 1 and 2 receptors (TGFBR1, TGFBR2), and association analysis of variants with diabetic nephropathy. BMC Med. Genet. 8, 5–15 (2007)PubMedCrossRef A.J. McKnight, D.A. Savage, C.C. Patterson, D. Sadlier, A.P. Maxwell, Resequencing of genes for transforming growth factor beta1 (TGFB1) type 1 and 2 receptors (TGFBR1, TGFBR2), and association analysis of variants with diabetic nephropathy. BMC Med. Genet. 8, 5–15 (2007)PubMedCrossRef
23.
go back to reference M. Buraczynska, I. Baranowicz-Gaszczyk, E. Borowicz, A. Ksiazek, TGF-beta1 and TSC-22 gene polymorphisms and susceptibility to microvascular complications in type 2 diabetes. Nephron Physiol 106, 69–75 (2007)CrossRef M. Buraczynska, I. Baranowicz-Gaszczyk, E. Borowicz, A. Ksiazek, TGF-beta1 and TSC-22 gene polymorphisms and susceptibility to microvascular complications in type 2 diabetes. Nephron Physiol 106, 69–75 (2007)CrossRef
24.
go back to reference D.P. Ng, J.H. Warram, A.S. Krolewski, TGF-beta 1 as a genetic susceptibility locus for advanced diabetic nephropathy in type 1 diabetes mellitus: an investigation of multiple known DNA sequence variants. Am. J. Kidney Dis. 41, 22–28 (2003)PubMedCrossRef D.P. Ng, J.H. Warram, A.S. Krolewski, TGF-beta 1 as a genetic susceptibility locus for advanced diabetic nephropathy in type 1 diabetes mellitus: an investigation of multiple known DNA sequence variants. Am. J. Kidney Dis. 41, 22–28 (2003)PubMedCrossRef
25.
go back to reference A. Valladares-Salgado, J. Angeles-Martinez, M. Rosas, J. Garcia-Mena, D. Utrera-Barillas, R. Gomez-Diaz, J. Escobedo-de la Pena, E.J. Parra, M. Cruz, Association of polymorphisms within the transforming growth factor-beta1 gene with diabetic nephropathy and serum cholesterol and triglyceride concentrations. Nephrology (Carlton) 15, 644–648 (2010)CrossRef A. Valladares-Salgado, J. Angeles-Martinez, M. Rosas, J. Garcia-Mena, D. Utrera-Barillas, R. Gomez-Diaz, J. Escobedo-de la Pena, E.J. Parra, M. Cruz, Association of polymorphisms within the transforming growth factor-beta1 gene with diabetic nephropathy and serum cholesterol and triglyceride concentrations. Nephrology (Carlton) 15, 644–648 (2010)CrossRef
26.
go back to reference Y.S. Wei, Y. Lan, Y.W. You, R.G. Tang, Y. Huang, L. Zhang, B. Luo, The serum level and the genotype of TGF-β1 in patients with type 2 diabetic nephropathy. Chin. J. Lab. Med. 28, 73–77 (2005) Y.S. Wei, Y. Lan, Y.W. You, R.G. Tang, Y. Huang, L. Zhang, B. Luo, The serum level and the genotype of TGF-β1 in patients with type 2 diabetic nephropathy. Chin. J. Lab. Med. 28, 73–77 (2005)
27.
go back to reference M. Wei, Y.S. Lu, S.J. Li, H.C. She, Study of relationship between TGF-β Leu10Pro polymorphism and diabetic nephropathy in type 2 diabetes. Chin. J. Diabetes 16, 538–540 (2008) M. Wei, Y.S. Lu, S.J. Li, H.C. She, Study of relationship between TGF-β Leu10Pro polymorphism and diabetic nephropathy in type 2 diabetes. Chin. J. Diabetes 16, 538–540 (2008)
28.
go back to reference K. Sharma, F.N. Ziyadeh, B. Alzahabi, T.A. McGowan, S. Kapoor, B.R. Kurnik, P.B. Kurnik, L.S. Weisberg, Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 46, 854–859 (1997)PubMedCrossRef K. Sharma, F.N. Ziyadeh, B. Alzahabi, T.A. McGowan, S. Kapoor, B.R. Kurnik, P.B. Kurnik, L.S. Weisberg, Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 46, 854–859 (1997)PubMedCrossRef
29.
go back to reference K. Sharma, F.N. Ziyadeh, Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am. J. Physiol. 267, F1094–F1101 (1994)PubMed K. Sharma, F.N. Ziyadeh, Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am. J. Physiol. 267, F1094–F1101 (1994)PubMed
30.
go back to reference B.B. Hoffman, K. Sharma, Y. Zhu, F.N. Ziyadeh, Transcriptional activation of transforming growth factor-beta1 in mesangial cell culture by high glucose concentration. Kidney Int. 54, 1107–1116 (1998)PubMedCrossRef B.B. Hoffman, K. Sharma, Y. Zhu, F.N. Ziyadeh, Transcriptional activation of transforming growth factor-beta1 in mesangial cell culture by high glucose concentration. Kidney Int. 54, 1107–1116 (1998)PubMedCrossRef
31.
go back to reference M. Suthanthiran, B. Li, J.O. Song, R. Ding, V.K. Sharma, J.E. Schwartz, P. August, Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proc. Natl. Acad. Sci. USA 97, 3479–3484 (2000)PubMedCrossRef M. Suthanthiran, B. Li, J.O. Song, R. Ding, V.K. Sharma, J.E. Schwartz, P. August, Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proc. Natl. Acad. Sci. USA 97, 3479–3484 (2000)PubMedCrossRef
32.
go back to reference S. Helmig, A. Belwe, J. Schneider, Association of transforming growth factor beta1 gene polymorphisms and asbestos-induced fibrosis and tumors. J. Investig. Med. 57, 655–661 (2009)PubMed S. Helmig, A. Belwe, J. Schneider, Association of transforming growth factor beta1 gene polymorphisms and asbestos-induced fibrosis and tumors. J. Investig. Med. 57, 655–661 (2009)PubMed
33.
go back to reference J. Gewaltig, K. Mangasser-Stephan, C. Gartung, S. Biesterfeld, A.M. Gressner, Association of polymorphisms of the transforming growth factor-beta1 gene with the rate of progression of HCV-induced liver fibrosis. Clin. Chim. Acta. 316, 83–94 (2002)PubMedCrossRef J. Gewaltig, K. Mangasser-Stephan, C. Gartung, S. Biesterfeld, A.M. Gressner, Association of polymorphisms of the transforming growth factor-beta1 gene with the rate of progression of HCV-induced liver fibrosis. Clin. Chim. Acta. 316, 83–94 (2002)PubMedCrossRef
34.
go back to reference B.A. Perkins, L.H. Ficociello, K.H. Silva, D.M. Finkelstein, J.H. Warram, A.S. Krolewski, Regression of microalbuminuria in type 1 diabetes. N. Engl. J. Med. 348, 2285–2293 (2003)PubMedCrossRef B.A. Perkins, L.H. Ficociello, K.H. Silva, D.M. Finkelstein, J.H. Warram, A.S. Krolewski, Regression of microalbuminuria in type 1 diabetes. N. Engl. J. Med. 348, 2285–2293 (2003)PubMedCrossRef
35.
go back to reference D.J. Newman, M.B. Mattock, A.B. Dawnay, S. Kerry, A. McGuire, M. Yaqoob, G.A. Hitman, C. Hawke, Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol. Assess. 9, iii–vi, xiii–163 (2005) D.J. Newman, M.B. Mattock, A.B. Dawnay, S. Kerry, A. McGuire, M. Yaqoob, G.A. Hitman, C. Hawke, Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol. Assess. 9, iii–vi, xiii–163 (2005)
Metadata
Title
Association between the T869C polymorphism of transforming growth factor-beta 1 and diabetic nephropathy: a meta-analysis
Authors
Hongxia Jia
Lili Yu
Bin Gao
Qiuhe Ji
Publication date
01-12-2011
Publisher
Springer US
Published in
Endocrine / Issue 3/2011
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-011-9503-0

Other articles of this Issue 3/2011

Endocrine 3/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.